Drug intelligence / Profile preview

MK-8892

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-8892 is an oral small molecule drug that was developed by Merck & Co for the treatment of pulmonary arterial hypertension and heart failure. It acts as a soluble guanylate cyclase (sGC) modulator, aiming to reduce pulmonary vascular resistance and improve cardiac function. The drug reached phase 1 clinical trials but development was discontinued due to strategic business decisions by the sponsor. No further development or approval has been reported[1][4][2].

Other names: MK 8892MK8892MK-8892

Targets

sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on MK-8892.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-8892.

Explore the full profile